Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 7, 2026

Camp4 Therapeutics Corp (CAMP)

A forensic read on Camp4 Therapeutics Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-1.4

Distress distance

Clean

Earnings quality

Forensic signals

-2.0

P / E (ttm)

-168.5%

ROE

$282M

Market cap

0.00%

Dividend yield

436.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Camp4 Therapeutics Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -1.4, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share count (stock split).

What the filings flag

n/m (stock split)

FY2024–FY2025

Share count (stock split). Diluted share count changed +548% over the last 1 year to FY2025, but that includes a large one-time change around FY2025 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +547.8%/yr figure isn't a real buyback/dilution read here.

114% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 114% of revenue in FY2025 — about $0.13 per diluted share. It is a real cost, but it is not a cash cost — no cash left the business, which is why operating cash flow adds it back. The bill lands on the share count instead, and this filer's count is not on file in enough years to say how much of the company changed hands to pay it.

Key fundamentals

Latest Revenue$3.5M

Revenue Growth YoY+436.5%

Net Margin-2298.5%

Free Cash Flow-$29.8M

Return on Equity-168.5%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Camp4 Therapeutics Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 7, 2026. Forensic signals flag probability, not certainty.